Market Quotes Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.
Medical product company, Genovi sees its rights issue fully subscribed
Tuesday, 22 May 2012
Genovis’ rights issue is fully subscribed and 81percent of the shares are subscribed with preferential rights.
In a press release from the company, the rights issue raised about Skr
12.1 million before issue expenses for Genovis. Statements of account
will be sent on May 22, 2012, to allot shares subscribed without
preferential rights, the company writes in a press release.
Genovis develops and sells innovative technologies from two unique
product portfolios. The first includes enzymes that facilitate
development and quality control for applications such as antibody-based
drugs. The products launched to date are aimed at customers who work
with development of drugs, new diagnostic methods and basic research.
By Scancomark.se Team
What do you think about this
article or us? Please leave a comment. Thank you!